Table 3 Summary of characteristics of approved RSV vaccines for older adults
From: Prevention of respiratory syncytial virus disease across the lifespan in Italy
RSVPreF [17] | RSVPreF3 [20] | mRNA-1345 [21] | |
|---|---|---|---|
Technology | Protein | Protein | mRNA |
Targeted antigen | Prefusion F protein from RSV subgroups A + B (bivalent) | Prefusion F protein from RSV subgroup A | Prefusion F protein from RSV subgroup A |
Adjuvated | No | Yes | No |
Content | 60 µg + 60 µg prefusion F protein | 120 µg prefusion F protein | 50 µg mRNA for prefusion F protein |
Number of doses | Single | Single | Single |